BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...hired Susan Rodriguez as chief commercial officer, a newly created role. She was CEO of Tolmar...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...for Gene Therapy” ). Approval for Tolmar’s early puberty therapy FDA approved an NDA for Tolmar...
...Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar Inc. Akebia...
BioCentury | Mar 14, 2016
Politics, Policy & Law

Value demonstration

...B) Gammagard Liquid immune globulin Autoimmune $212.0 Eli Lilly Erbitux cetuximab Cancer $211.8 AbbVie / Tolmar...
BioCentury | Jul 16, 2012
Finance

Paring down QLT

...to receive $105 million in contingent payments tied to prostate cancer treatment Eligard leuprolide from Tolmar Inc....
BioCentury | Jun 11, 2012
Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

...subsequently acquired by QLT Inc. (TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.). In 2009, QLT divested Eligard to Tolmar Inc....
BioCentury | Jun 11, 2012
Company News

Vigilant Biosciences management update

...Diagnostic Hired: David Barshis, a director, as CEO; formerly COO of Zila Inc. , which Tolmar Inc....
BioCentury | Jun 8, 2012
Company News

Vigilant Biosciences names Barshis CEO

...the former COO of dental and diagnostic company Zila Inc. , which was acquired by Tolmar Inc....
BioCentury | Jan 24, 2011
Company News

Astellas, Tolmar sales and marketing update

...divested Eligard to Tolmar (see BioCentury, July 26, 2010). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Tolmar Inc....
BioCentury | Jul 26, 2010
Company News

MediGene, Astellas sales and marketing update

...2009, QLT divested Eligard to Tolmar Inc. (Fort Collins, Colo.). The deal terminates MediGene's obligations to Tolmar...
BioCentury | Nov 2, 2009
Finance

EPS watch

...land. Figures do not include prostate cancer drug Eligard leuprolide acetate, which QLT divested to Tolmar Inc....
Items per page:
1 - 10 of 15
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...hired Susan Rodriguez as chief commercial officer, a newly created role. She was CEO of Tolmar...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...for Gene Therapy” ). Approval for Tolmar’s early puberty therapy FDA approved an NDA for Tolmar...
...Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar Inc. Akebia...
BioCentury | Mar 14, 2016
Politics, Policy & Law

Value demonstration

...B) Gammagard Liquid immune globulin Autoimmune $212.0 Eli Lilly Erbitux cetuximab Cancer $211.8 AbbVie / Tolmar...
BioCentury | Jul 16, 2012
Finance

Paring down QLT

...to receive $105 million in contingent payments tied to prostate cancer treatment Eligard leuprolide from Tolmar Inc....
BioCentury | Jun 11, 2012
Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

...subsequently acquired by QLT Inc. (TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.). In 2009, QLT divested Eligard to Tolmar Inc....
BioCentury | Jun 11, 2012
Company News

Vigilant Biosciences management update

...Diagnostic Hired: David Barshis, a director, as CEO; formerly COO of Zila Inc. , which Tolmar Inc....
BioCentury | Jun 8, 2012
Company News

Vigilant Biosciences names Barshis CEO

...the former COO of dental and diagnostic company Zila Inc. , which was acquired by Tolmar Inc....
BioCentury | Jan 24, 2011
Company News

Astellas, Tolmar sales and marketing update

...divested Eligard to Tolmar (see BioCentury, July 26, 2010). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Tolmar Inc....
BioCentury | Jul 26, 2010
Company News

MediGene, Astellas sales and marketing update

...2009, QLT divested Eligard to Tolmar Inc. (Fort Collins, Colo.). The deal terminates MediGene's obligations to Tolmar...
BioCentury | Nov 2, 2009
Finance

EPS watch

...land. Figures do not include prostate cancer drug Eligard leuprolide acetate, which QLT divested to Tolmar Inc....
Items per page:
1 - 10 of 15